RxDoctor Payments Data

Charles Davis, PA

Medical · Athens, GANPI 1952397564

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.4% of the total across 817 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 9.1% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,555in general payments, 2019–2025

Across 817 payments — averaging $20.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Merck$1K
  • GSK$852
  • Johnson & Johnson$826
  • Gilead$808
  • Bristol Myers Squibb$694
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$15,95796%
  • Education$5984%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis73$1,505
Merck54$1,197
GSK52$852
Johnson & Johnson(2 entities)45$826
Gilead(2 entities)41$808
Bristol Myers Squibb32$694
Incyte Corporation27$639
Pharmacyclics LLC, An Abbvie Company32$593
Daiichi Sankyo Inc.27$578
Pfizer39$562
Bayer19$522
Sanofi21$443
Eisai Inc.21$418
Jazz Pharmaceuticals Inc.15$408
Takeda Pharmaceuticals U.S.A., Inc.16$397
Seagen Inc.24$392
Exelixis Inc.23$372
AbbVie13$367
AstraZeneca(2 entities)16$367
Genentech USA, Inc.19$364
Amgen17$312
Astellas Pharma US Inc9$255
Sobi, Inc12$234
Stemline Therapeutics Inc.10$231
Tersera Therapeutics LLC10$224
Adaptive Biotechnologies Corporation9$216
Karyopharm Therapeutics Inc.12$214
Epizyme, Inc.11$201
Rigel Pharmaceuticals, Inc.9$173
Blueprint Medicines Corporation8$166
Regeneron Healthcare Solutions, Inc.7$143
Beigene USA, Inc.6$129
AVEO Pharmaceuticals, Inc.6$123
Sumitomo Pharma America, Inc.6$121
Ipsen Biopharmaceuticals, Inc5$109
Sanofi-aventis U.S. LLC1$99
Puma Biotechnology, Inc.6$98
ADC Therapeutics America, Inc.5$94
Beone Medicines USA, Inc.5$93
EMD Serono, Inc.5$86
Lilly USA, LLC4$75
Boehringer Ingelheim3$62
E.r. Squibb & Sons, L.L.C.4$60
Morphosys, US Inc.3$57
Acrotech Biopharma Inc.3$51
G1 Therapeutics, Inc.3$50
Deciphera Pharmaceuticals Inc.3$49
Pharmaessentia USA Corporation2$43
Taiho Oncology, Inc.1$35
Apellis Pharmaceuticals, Inc.2$32
Geron Corporation1$27
Cycle Pharmaceuticals Inc1$26
Janssen Scientific Affairs, LLC1$26
Sun Pharmaceutical Industries Inc.1$25
Dendreon Pharmaceuticals LLC1$24
Mirati Therapeutics, Inc.1$21
Immunocore Limited1$21
Spectrum Pharmaceuticals Inc.1$21
Avyxa Pharma, LLC1$20
Syndax Pharmaceuticals, Inc.1$20

How this compares

$16,555 in reported general payments places this provider in the 95th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Medicare billing

Part B allowed, 2024
$118,002
Medicare patients
68
Services billed
4,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide64$747,628
VenclextaVenetoclax23$316,937
XtandiEnzalutamide22$302,650
PomalystPomalidomide12$266,164
SprycelDasatinib14$265,090
IbrancePalbociclib15$222,686
Lenalidomide18$200,595
EliquisApixaban52$36,193
OrgovyxRelugolix11$30,103
XareltoRivaroxaban38$26,373
Dexamethasone48$1,344
Hydroxyurea33$1,073
Ondansetron OdtOndansetron85$1,031
Acyclovir77$644
Prochlorperazine Maleate49$552

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$694$747,62864 claims
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$60$531,25526 claims
AbbVieVenclexta$367$316,93723 claims
Astellas Pharma US IncXtandi$255$302,65022 claims
PfizerIbrance, Eliquis$562$258,87867 claims
Sumitomo Pharma America, Inc.Orgovyx$121$30,10311 claims
Johnson & JohnsonXarelto$826$26,37338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 950 medical providers in Georgia.

Other medical in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →